1. Introduction {#sec1}
===============

Inherited Retinal Dystrophies (IRDs) are a heterogeneous group of eye disorders characterized by rod and/or cone photoreceptor cells degeneration, which include Retinitis Pigmentosa (RP), Leber Congenital Amaurosis (LCA), Stargardt Disease (STGD), Best Macular Dystrophy (BMD), and syndromic forms such as Usher Syndrome (USH). The overall prevalence of these disorders is \~1 in 4,000 individuals for RP, \~1 in 90,000 individuals for LCA and USH, \~1 in 5,000--10,000 individuals for STGD, and 1/5000--1/67000 for BMD (<http://www.orpha.net>). Classification of IRDs considers the principal site of retinal dysfunction (rod, cone, retinal pigment epithelium, or inner retina), the mode of inheritance, the underlying gene defect, typical age of onset, rate of progression, and association with systemic syndromes. The genetic bases of IRDs are highly heterogeneous, with almost 150 genes currently known \[RetNet, <https://sph.uth.edu/retnet/>\] and a wide clinical and genetic overlap among the different disorders, with high phenotypic variability and genes associated with more than one phenotype. The inheritance of these diseases is also complex, with autosomal dominant (AD), autosomal recessive (AR), X-linked (XL), and even digenic patterns \[[@B1]\]. The extensive clinical and genetic heterogeneity in IRD, along with the variable age of onset, the incomplete penetrance, and unclear inheritance, hamper clinical diagnosis.

Recently, Next-Generation Sequencing (NGS) has been used for the genetic diagnosis of retinal diseases \[[@B2]--[@B6]\] and has been reported as a cost-effective approach \[[@B7], [@B8]\] with a wide range of reported mutation detection rates related to differences in number of genes analyzed, NGS platform, and cohort size but above all composition of the study case phenotypes. We therefore present a multidisciplinary approach coupled with a comprehensive NGS amplicon-based strategy to explore IRD genetic complexity and evaluate genotype-phenotype correlations.

2. Patients and Methods {#sec2}
=======================

This study was approved by the ethics committee (Comitato Etico di Modena, Modena, Italy). The procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2000, and samples were obtained after patients had provided written informed consent.

A total of 109 samples were collected, including 88 IRDs affected probands with unknown molecular diagnosis and 21 healthy family members ([Table 1](#tab1){ref-type="table"}). Subjects were recruited at the Medical Genetics Unit of the University Hospital of Modena (70 samples), at the Medical Genetics Unit of Parma University Hospital (15 samples) and Medical Genetics Unit of Policlinico Sant\'Orsola Malpighi, Bologna (24 samples). All subjects underwent a complete ophthalmologic examination (visual acuity, anterior segment and fundus examination, spectral domain-optical coherence tomography, electroretinogram, and/or electrooculogram) followed by genetic counseling. When indicated fundus autofluorescence imaging and visual field were also performed. Clinical information for the patients with identified pathogenic mutations is shown in Supplementary Table  1 (in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/6341870>). Clinical diagnoses of participating subjects included RP, USH (hearing impairment + RP), LCA, STGD, BMD, and IRDs not otherwise specified or with imprecisely defined clinical diagnosis. Four control patients with known molecular diagnosis were used to validate our method.

2.1. AmpliSeq Panel Design and Ion Torrent™ PGM™ Library Preparation and Sequencing {#sec2.1}
-----------------------------------------------------------------------------------

The Ion AmpliSeq technology (Life Technologies Ltd., Paisley, UK) was used to design a panel of 72 genes (Supplementary Table  2) associated with the following IRD forms: RP, LCA, STGD, BMD, and USH \[RetNet, <https://sph.uth.edu/retnet/>\]. The Ion AmpliSeq Designer tool (<https://www.ampliseq.com/browse.action>) generated an optimized primers design encompassing the coding DNA sequence of the selected genes, for a total of 1.649 amplicons divided into two pools to optimize coverage and multiplex PCR conditions. Libraries were prepared using the Ion AmpliSeq Library Kit 2.0 starting from 15 ng of gDNA/pool according to manufacturer\'s recommendations. Template preparation was performed using an Ion OneTouch™ 2 System following the latest version of the manufacturer\'s manuals. The template positive Ion Sphere Particles (ISPs+) were sequenced on an Ion Torrent Personal Genome Machine® (PGM) System (Life Technologies Ltd., Paisley, UK) using the Ion 318™ Chip kit v2 following the Ion PGM Sequencing 200 Kit v2 manual.

2.2. Sanger Sequencing {#sec2.2}
----------------------

Sanger sequencing was performed to validate*CNGB1* c.875-5_891dup mutation (identified with an anomalous distribution of NGS reads attributable to amplification problems due to the insertion itself located at the end of the target region) and to sequence*RPGR*ORF15 partially uncovered by the NGS panel. Primers for PCR and sequencing are shown in Supplementary Table  3. The following conditions were used: a 50 *μ*L PCR reaction containing 100 ng of DNA, 100 pmol of forward and reverse primers, 5 *μ*L of buffer, and 0.5 *μ*L of Taq Expand High Fidelity™ DNA Polymerase (Roche). PCR amplification (see Supplementary Table  3) was performed using a Gene Amp PCR System 9700 (Applied Biosystems, California, USA). The resultant amplicons were purified using High Pure PCR Product Purification Kit (Roche). Additional primers for*RPGR* sequencing were used. The sequencing reactions were performed with BigDye Terminator v1.0 (Life Technologies) and run on ABI PRISM® 3130XL Genetic Analyzer (Life Technologies). Due to sequence composition and technical difficulties, part of*RPGR* ORF15 (\~250 bp, chrX: 38145343--38145593) could not be accurately sequenced with Sanger sequencing.

2.3. Data Analysis {#sec2.3}
------------------

Samples were processed using the Ion Torrent Suite™ (TS) Software for raw data processing and sequence alignment to the human genome reference sequence hg19. The TS Variant Caller was used for the detection of germline variants that were subsequently analyzed using the following optimized filtering and annotation pipeline. Annovar \[[@B9]\] and Variant Effect Predictor (VEP) \[[@B10]\] were used to functionally annotate the detected variants, retrieving RefSeq gene annotation, dbSNP rs identifiers, ClinVar accession, and allele frequency observed in the population (1000-Genome Project, NHLBI GO Exome Sequencing Project ESP6500SI-V2, Exome and Aggregation Consortium ExAC 0.3). Variants with low coverage or low frequency (\<30 reads or \<30%, resp.) were filtered out. The synonymous variants and variants having an allele frequency greater than 1% reported in the population were discarded as well. In addition, an internal database, built with all variants present in our cohort of processed samples, allowed recognizing and classifying as polymorphisms variants not listed in public databases. Variants were further annotated with conservation scores and functional predictions listed in dbNSFP \[[@B11]--[@B13]\], a database which compiles scores from various prediction algorithms, among which are SIFT, Polyphen2, LRT, MutationTaster, MutationAssessor, and FATHMM. Retina International ([http://www.retina-international.org/](http://www.retina-international.org)), RPGR database (<http://rpgr.hgu.mrc.ac.uk/index.php?select_db=RPGR>), CEP290base (<http://cep290base.cmgg.be/>), and BEST1 LOVD database (<http://www-huge.uni-regensburg.de/BEST1_database>) were used to explore additional annotations and literature information, if present. Splice-altering predictions were obtained using the online tools Human Splicing Finder (HSF 3.0) \[[@B14]\] and NNSPLICE 0.9 \[[@B15]\] and the databases dbscSNV \[[@B16]\] and SPIDEX \[[@B17]\], which provide predicted effects for all of the potential variants within splicing consensus regions or across the entire genome, respectively. For the prioritization of pathogenetic mutations, the evaluation of inheritance mode was taken into account, along with segregation information coming from the sequencing of healthy family members, if available.

NGS procedure and data analysis were tested on the four control samples with known molecular diagnosis as proof of concept. In all cases the previously identified variants were correctly detected and prioritized as pathogenic variants.

3. Results {#sec3}
==========

A cohort of 109 samples ([Table 1](#tab1){ref-type="table"}), including 88 IRDs affected probands without molecular diagnosis and 21 unaffected family members, was analyzed by the newly developed system based on NGS and data analysis. A total of 19 sequencing runs were performed (6 samples/Ion Chip 318), obtaining on average a mean coverage of 450 mapped reads, with 92% mean uniformity and 97.6% (SD ± 1.4) of target regions covered at least 30x (96.2% \> 50x). For each sample, 242 raw variants were detected on average. Annotation and filtering procedure resulted in the identification of possibly causative mutations in 59.1% of patients (*n* = 52/88) ([Table 2](#tab2){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). The majority of the obtained molecular diagnoses were consistent with the subject\'s clinical presentation and family history.

We found pathogenic mutations in 16 genes, with the most recurrent being*ABCA4* for STGD and*USH2A* for RP/USH patients. The majority of the mutated genes were inherited with an AR pattern (78.9%), followed in order by AD (11.5%) and XL (9.6%) inheritance. The majority of cases displaying recessive inheritance were compound heterozygous of two different pathogenic variants, in line with the low frequency of consanguineous marriages in Italy

Identified candidate pathogenic mutations are shown in [Table 3](#tab3){ref-type="table"}. Overall, 63 different mutations were identified: 62.5% of variants were already reported in previous studies, while 37.5% were novel. Among the list of novel variants, 56% were missense predicted to have deleterious protein functional effect by the prediction algorithms described in the Patients and Methods (predicted to be damaging by at least three of the applied algorithms), and 44% were frameshift, nonsense, or splice-site mutations that might severely affect protein function. Notably, 12% of identified variants were located within splicing consensus regions, and additional 12% were exonic variants predicted to alter splicing through enhancer/silencer motif modification or the creation of new potential donor/acceptor sites.

[Table 2](#tab2){ref-type="table"} summarizes the mutation detection rates obtained for the different clinical subtypes of our study cohort. The highest diagnostic yields were achieved for BMD, LCA, USH, and STGD patients with well-defined clinical diagnosis, where the number of known genes associated with each disease is relatively limited.

For BMD cases, all diagnosed patients were heterozygous for mutations on*BEST1*. Three patients (mother and son) were found to harbour a novel*BEST1* missense mutation c.80G\>C (p.Ser27Thr) located in the immediate N-terminus, in one of the four mutational hotspots regions in the highly conserved N-terminal half of the protein \[[@B18]\] and predicted to be deleterious by all interrogated algorithms.

For STGD patients, genetic diagnosis was achieved in 11 out of 14 (78.5% of the cases). All diagnosed patients in our cohort carried mutations on*ABCA4*. In 75% of the unsolved cases at least one*ABCA4* pathogenic allele was identified, suggesting the presence of disease-causing mutations lying outside the coding sequence covered by our panel, as reported in a previous study \[[@B19]\].

In LCA patients, causative mutations were identified in*CEP290, RPE65, RPGRIP1,* and*CRX* genes, and only one case remained unsolved (20% of the total LCA cases), whereas all Usher 2 syndrome cases were found to carry mutations in USH2A gene.

For RP patients, genetic diagnosis was achieved in 27 out of 45 (60% of the cases), involving mutations in 11 different genes: confirming that these phenotypes are genetically heterogeneous ([Figure 1](#fig1){ref-type="fig"}). Dominant mutations were identified in*RHO* gene, whereas*USH2A, CNGB1,* and*TULP1* were the most recurrently mutated genes in ARRP. X-linked inheritance was established for 5 RP male patients (4 probands had mutations in*RPGR*, whereas one had a mutation in RP2). The identification of*USH2A* as the defective gene in patients with initial clinical diagnosis of RP was followed by audiometric testing to establish if there were any hearing deficiencies. A hearing impairment was found in 2 cases out of 5 leading to clinical reassessment and final diagnosis of USH ([Table 2](#tab2){ref-type="table"}).

For patients with IRD without a defined clinical diagnosis or with unclear disease manifestations, we identified causative mutations in 7 out of 17 probands (23.5% of the total IRD cases). In two cases the molecular results allowed a refined clinical diagnosis: a compound heterozygosity of two mutations in*CEP290* led to a genetic diagnosis of LCA in a patient with initial diagnosis of North Carolina or Stargardt macular dystrophy, whereas a homozygous pathogenic variant in*ABCA4* was found in a patient with tapetoretinal degeneration.

In 36 patients (12 familiar and 24 sporadic) the molecular analysis did not achieve any definitive result, even after the analysis of the healthy family members, which was performed in 8 cases. Half of the cases with a negative test result (18 out of 36) were affected by RP. The additional analysis of the*RPGR* ORF15 (a mutational hotspot which was nonsufficiently covered in our panel) for the male patients with a sporadic or suspected X-linked pattern of inheritance (10 patients) by Sanger sequencing yielded no additional mutations.

4. Discussion {#sec4}
=============

The results of the present study confirm that high-throughput Next-Generation Sequencing represents a comprehensive cost-effective approach for the molecular diagnosis of Inherited Retinal Dystrophies (IRDs), achieving a molecular diagnosis for 59.1% of the studied cases. More specifically, among the different clinical phenotypes, the highest detection rates were achieved for BMD, LCA, USH, and STGD patients, in whom the genetic test clearly confirmed the clinical diagnoses ([Table 2](#tab2){ref-type="table"}). The results of the RP and of the not defined IRD cohorts, instead, demonstrated the high genetic heterogeneity of this diseases and the essential contribution of our NGS analysis to achieving an accurate diagnosis, with the involvement of 12 different genes in 28 sporadic cases. Revision of the initial diagnosis, performed for 9.6% of the genetically diagnosed patients, further emphasizes the importance of a comprehensive genotype/phenotype analysis to unravel the extensive heterogeneity of these diseases. Notably, a remarkable fraction of identified variants are splice-altering mutations (25% of the total mutation burden, 16 out of 64), located within splicing consensus regions, or exonic variants predicted to cause enhancer/silencer motif modification or the creation of new potential donor/acceptor, which are amenable to the antisense-mediated splicing-correction approaches, as recently reported for several genetic diseases, including*CEP290*-caused LCA \[[@B20], [@B21]\].

The prevalence of IRD and most importantly the frequency of gene mutations causing those diseases are not well characterized in Italy and only few data have been reported \[[@B22]--[@B24]\].*RPE65, CRB1,* and*GUCY2D* were identified as the most prevalent mutated genes in Italian LCA patients \[[@B22]\] and*RHO* was reported to be the gene most commonly responsible for ADRP \[[@B23]\] and*EYS* the most recurrent for nonsyndromic ARRP and sporadic cases \[[@B24]\]. Our study contributes only partially to the knowledge of the gene mutation frequencies, since each IRD type is represented by small cohorts of cases (i.e., the LCA and dominant RP phenotypes were accounted for by 5 and 6 cases, resp.), and some probands of other ethnicities have been included too. Indeed, regarding LCA, we identified mutations in CEP290,*RPE65*,*CRX*, and*RPGRIP1* genes.

For ADRP,*RHO* was identified to be responsible for the phenotype in one case, whereas, in ARRP and sporadic RP,*USH2A, CNGB1,* and*TULP1* were the most recurrently mutated genes.*RPE65* mutations were found in two ARRP cases: in one more case, still unsolved, a single*RPE65* heterozygous pathogenic variant was found.*ROM1* compound heterozygosity was established in one RP proband, suggesting a mechanism of recessive inheritance for this gene associated with dominant and digenic forms. X-linked inheritance was established for 5 RP affected probands, with*RPGR* and*RP2* identified as the disease-causing gene in 4 cases and 1 case, respectively. All BMD diagnosed patients were heterozygous for mutations on*BEST1* gene, the major gene responsible for Best\'s juvenile form \[[@B25]\], whereas the 78.5% of patients with clinically diagnosed STGD carried pathogenic variants on*ABCA4*\[[@B26]\].

Similarly to a recent study \[[@B6]\], the clinical sensitivity of our NGS analysis was not uniform, with the highest diagnostic yields obtained in conditions where the disease-causing genes have been nearly all identified.

Direct comparison of our findings with other recently published NGS studies \[[@B2]--[@B6], [@B27]\] is not straightforward, due to differences in the number of genes analyzed but especially due to composition and relative representation of the different phenotypes in the patients cohorts. However, the finding of*USH2A* and*ABCA4* as the most mutated genes for RP/USH and STGD patients is consistent with previous reports \[[@B27]--[@B29]\]. In our RP cohort,*USH2A* is followed by*CNGB1* and*RPGR*. These two genes, already reported among the most frequently mutated genes in IRD patients \[[@B29]\], were not highly frequently altered in the Saudi population \[[@B6]\] or in a large cohort of Western European and South Asian individuals \[[@B27]\]. Also, we did not find any alteration in*EYS*, one of the top three genes contributing to IRD in other populations \[[@B28], [@B29]\].

The different gene alterations identified in our LCA cohort (*CEP290, RPE65, RPGRIP1,* and*CRX* genes) were consistent with the different disease manifestations of the analyzed patients, in accordance with the specific clinical features described for each of the LCA-associated genes \[[@B30], [@B31]\]. Less direct is the correlation between the genes involved and the phenotypic features in RP, due to the known contribution of environmental factors to late-childhood- and adult-onset-diseases.

Allelic heterogeneity, with different mutations in the same gene causing different phenotypes, is evident also in*USH2A*-related retinal disease. Genotype-phenotype correlations observed in our cohort were in accordance with the allelic hierarchy proposed in a recent study \[[@B32]\], supporting the model that USH represents the null phenotype consequent upon severe*USH2A* defects, whereas milder mutations in at least one allele result in a pure retinal phenotype associated with normal auditory function.

IRD genetic heterogeneity, reflected in the identification of mutations in many genes with a considerable number of previously undescribed alterations, supported the conclusion that molecular diagnosis of these disorders should rely on massive parallel multigene sequencing. Nevertheless, for 36 probands, including 12 familiar cases and 24 unrelated probands, our NGS procedure did not result in the identification of a clear genetic cause of the disease. Some subjects may have mutations that cannot be detected by our amplicon-based approach, such as deep intronic mutations, copy-number variations, or large deletions. In the perspective of the design of a more complete new version of the panel, additional deep intronic regions reported in the literature as carrying disease-causing mutations \[[@B19], [@B33], [@B34]\] or a higher exon padding (5 bp in our design, up to 100 bp available in the current pipeline version of the Ion AmpliSeq Designer tool) could be implemented. Moreover, technical limitations, including the difficult amplification of*RPGR* ORF15, a mutational hotspot for X-linked RP, may have accounted for some of the missed diagnosis (our panel is presently covering only 30% of this critical exon), but the addition of the specific analysis by Sanger sequencing of the ORF15 of the*RPGR* gene in 10 males patients, with sporadic/X-linked RP and previously testing negative for pathogenic mutations using our NGS panel, did not reveal any mutation in the analyzed region. Finally, as an improvement to further support the pathogenicity of novel mutations identified in probands, the analysis of both affected and unaffected family member should be performed, when possible.

In some of the patients who tested negative we however identified single potentially pathogenic heterozygous mutations in recessive genes or novel heterozygous missense variants in dominant genes with unknown significance, lacking the appropriate level of evidence to classify them as disease-causing or not in concordance with patients\' clinical presentations or family data. The contribution of these variants in combination with deep intronic mutations or large deletions is suspected but could not be demonstrated with the present technique.

Database incompleteness further complicates variant interpretation. Two probands with BMD phenotype and*BEST1* mutation were found to harbour also heterozygous mutation in*RHO* (c.578C\>T, p.Thr193Met), which was predicted to be damaging and listed as associated with ADRP in a public database \[<http://www.retina-international.org/sci-news/databases/mutation-database>\] but in our cohort was carried also by healthy subject, reinforcing the need of a critical interpretation of the molecular findings in view of the phenotypic features of the patients with IRD until a more thorough knowledge of the frequency of the variants and a critical amount of data present in the public disease databases are reached.

In conclusion, by presenting profoundly different mutation rates varying according to the clinical diagnosis and by reporting 9.61% of cases of reassessment of the initial diagnosis on the basis of the results of the test, our study reinforces the need of a multidisciplinary work-up before and after the genetic testing, due to the implications of the results in terms of risk assessment for family members and inclusion in gene-based clinical trials.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Clinical information for the patients with identified pathogenic mutations is reported in Supplementary Table1. Supplementary Table2 lists the genes included in the designed NGS panel and their associated retinal disease. Primers used for PCR and Sanger sequencing are reported in Supplementary Table 3.
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###### 

Patients cohort.

  Clinical diagnosis   Number of cases   Healthy relatives   Familiar Cases (number of families)   Presumed inheritance in family   Sex   Age at genetic counseling                          
  -------------------- ----------------- ------------------- ------------------------------------- -------------------------------- ----- --------------------------- --- ---- ---- -------- ------
  BMD                  4                                     2 (1)                                                                  4                                     1    3    12--65   58
  LCA                  5                 5                                                         1                                      4                               2    3    5--85    9
  STGD                 14                                    6 (3)                                                                        14                              5    9    8--59    28
  RP                   45                12                  9 (4)                                 14                               6     20                          5   25   20   2--73    47.5
  USH                  3                                                                                                                  3                               2    1    33--53   51
  nd IRD               17                4                   6 (2)                                 6                                6     5                               13   4    2--62    35
  Total                88                21                  23 (10)                               21                               16    46                          5   48   40   2--85    37

BMD: Best Macular Dystrophy; LCA: Leber Congenital Amaurosis; STGD: Stargardt disease; RP: Retinitis Pigmentosa; USH: Usher syndrome; nd IRD: inherited retinal degeneration not otherwise specified without precisely defined diagnosis; AD: autosomal dominant; AR: autosomal recessive; XL: X-linked; M: male; F: female.

###### 

Diagnostic yields for the clinical subtypes of this study.

  -------------------------------------------------------------------------------------------
  Clinical\   Cases\   Genetic\          Unsolved\     Clinical reassessment\   Diagnostic\
  diagnosis   (*n*)    diagnosis (*n*)   cases (*n*)   (final diagnosis)        yield (%)
  ----------- -------- ----------------- ------------- ------------------------ -------------
  BMD         4        4                 ---                                    100

  LCA         5        4                 1                                      80

  STGD        14       11                3                                      78.5

  RP          45       27                18            2 (USH)                  60.0

  USH         3        3                 ---                                    100

  nd IRD      17       3                 14            3 (ACHM, LCA, STGD)      17.6

  Total       88       52                36            5                        59.1
  -------------------------------------------------------------------------------------------

BMD: Best Macular Dystrophy; LCA: Leber Congenital Amaurosis; STGD: Stargardt Disease; RP: Retinitis Pigmentosa; USH: Usher Syndrome; nd IRD: inherited retinal degeneration not otherwise specified without precisely defined diagnosis; ACHM: Achromatopsia.

  ----------------------- ------------------------- -------------------- ----------------------- ------------------------------------- --------------------------------- ------------------------------ ------------------------- ---------------- -------------------------
  Patient ID              Family                    Clinical diagnosis   Clinical reassessment   Genotype                              Inheritance                       Gene                           Mutation type             Region           cds change

                                                                                                                                                                                                                                                   

  IRD027                                            STGD                                         Comp Het                              ar                                *ABCA4*                        Splice_region             INTRON_40        c.5714+5G\>A

  *ABCA4*                 Frameshift                EXON_11              c.1375delA                                                                                                                                                                

  IRD036                  Familiar case             STGD                                         Comp Het                              ar                                *ABCA4*                        Stop_gained               EXON_14          c.2099G\>A

  *ABCA4*                 Splice_region syn         EXON_6               c.768G\>T                                                                                                                                                                 

  IRD037                  STGD                                           Comp Het                ar                                    *ABCA4*                           Stop_gained                    EXON_14                   c.2099G\>A       

  *ABCA4*                 Splice_region syn         EXON_6               c.768G\>T                                                                                                                                                                 

  IRD042                  Familiar case             STGD                                         Comp Het                              ar                                *ABCA4*                        Missense                  EXON_42          c.5882G\>A

  *ABCA4*                 Missense                  EXON_6               c.634C\>T                                                                                                                                                                 

  IRD043                  STGD                                           Comp Het                ar                                    *ABCA4*                           Missense                       EXON_42                   c.5882G\>A       

  *ABCA4*                 Missense                  EXON_12              c.1622T\>C                                                                                                                                                                

  IRD050                                            STGD                                         Comp Het                              ar                                *ABCA4*                        Missense                  EXON_16          c.2461T\>A

  *ABCA4*                 Missense                  EXON_15              c.2300T\>A                                                                                                                                                                

  IRD054                                            STGD                                         Comp Het                              ar                                *ABCA4*                        Stop_gained               EXON_47          c.6445C\>T

  *ABCA4*                 Missense                  EXON_42              c.5882G\>A                                                                                                                                                                

  IRD055                                            STGD                                         Comp Het                              ar                                *ABCA4*                        Missense                  EXON_19          c.2842C\>T

  *ABCA4*                 Missense                  EXON_15              c.2300T\>A                                                                                                                                                                

  IRD061                                            STGD                                         Comp Het                              ar                                *ABCA4*                        Missense                  EXON_42          c.5882G\>A

  *ABCA4*                 Missense                  EXON_28              c.4139C\>T                                                                                                                                                                

  IRD062                                            STGD                                         Comp Het                              ar                                *ABCA4*                        Missense                  EXON_42          c.5882G\>A

  *ABCA4*                 Missense                  EXON_16              c.2549A\>G                                                                                                                                                                

  IRD073                                            nd IRD               STGD                    Hom                                   ar                                *ABCA4*                        Missense                  EXON_19          c.2894A\>G

  IRD077                                            STGD                                         Comp Het                              ar                                *ABCA4*                        Missense                  EXON_37          c.5285C\>A

  *ABCA4*                 Missense                  EXON_15              c.2300T\>A                                                                                                                                                                

  IRD047                                            BMD                                          Het                                   ad                                *BEST1*                        Missense                  EXON_2           c.73C\>T

  IRD057                  Familiar case             BMD                                          Het                                   ad                                *BEST1*                        Missense                  EXON_2           c.80G\>C

  IRD058                  BMD                                            Het                     ad                                    *BEST1*                           Missense                       EXON_2                    c.80G\>C         

  IRD064                                            BMD                                          Het                                   ad                                *BEST1*                        Missense                  EXON_2           c.80G\>C

  IRD010                                            LCA                                          Comp Het                              ar                                *CEP290*                       Missense                  EXON_33          c.4237G\>C

  *CEP290*                Frameshift                EXON_23              c.2390delA                                                                                                                                                                

  IRD066                                            RP                                           Comp Het                              ar                                *CEP290*                       Stop_gained               EXON_48          c.6640A\>T

  *CEP290*                Frameshift                EXON_14              c.1219_1220delAT                                                                                                                                                          

  IRD072                                            nd IRD               LCA                     Comp Het                              ar                                *CEP290*                       Missense                  EXON_14          c.1298A\>G

  *CEP290*                Frameshift                EXON_3               c.164_167delCTCA                                                                                                                                                          

  IRD039                                            RP                                           Hom                                   ar                                *CNGB1*                        Frameshift                EXON_13          c.875-5_891dup

  IRD052                                            RP                                           Comp Het                              ar                                *CNGB1*                        Missense                  EXON_29          c.2957A\>T

  *CNGB1*                 Frameshift                EXON_13              c.875-5_891dup                                                                                                                                                            

  IRD068                                            RP                                           Comp Het                              ar                                *CNGB1*                        Splicing, syn             EXON_26          c.2526C\>T

  *CNGB1*                 Missense                  EXON_21              c.2153G\>C                                                                                                                                                                

  IRD085                                            RP                                           Hom                                   ar                                *CNGB1*                        Missense                  EXON_23          c.2284C\>T

  IRD032                                            nd IRD               ACHM                    Comp Het                              ar                                *CNGB3*                        Splice_donor              INTRON_13        c.1578+1G\>A

  *CNGB3*                 Frameshift                EXON_10              c.1148delC                                                                                                                                                                

  IRD029                  Familiar case             RP                                           Hom                                   ar                                *CRB1*                         Missense                  EXON_5           c.2200G\>A

  IRD030                  RP                                             Hom                     ar                                    *CRB1*                            Missense                       EXON_5                    c.2200G\>A       

  IRD031                  RP                                             Hom                     ar                                    *CRB1*                            Missense                       EXON_5                    c.2200G\>A       

  IRD035                                            LCA                                          Het                                   ad                                *CRX*                          Frameshift                EXON_4           c.514delC

  IRD008                                            RP                                           Hom                                   ar                                *PDE6B*                        Splice_region             EXON_18          c.2193+1delG

  IRD013                                            RP                                           Comp Het                              ar                                *PDE6B*                        Missense                  EXON_4           c.794G\>A

  ar                      *PDE6B*                   Intron               INTRON_8                c.1108-10G\>A                                                                                                                                     

  IRD026                                            RP                                           Het                                   ad                                *RHO*                          Missense                  EXON_3           c.568G\>T

  IRD016                                            RP                                           Comp Het                              ar                                *ROM1*                         Missense                  EXON_1           c.178C\>A

  *ROM1*                  Missense                  EXON_1               c.323C\>T                                                                                                                                                                 

  IRD033                                            RP                                           Hem                                   xl                                *RP2*                          Frameshift                EXON_2           c.382_383delTT

  IRD076                                            RP                                           Hom                                   ar                                *RPE65*                        Missense                  EXON_2           c.65T\>C

  IRD001                                            RP                                           Comp Het                              ar                                *RPE65*                        Missense                  EXON_2           c.65T\>C

  *RPE65*                 Frameshift                EXON_9               c.893delA                                                                                                                                                                 

  IRD074                                            LCA                                          Hom                                   ar                                *RPE65*                        Missense                  EXON_5           c.430T\>G

  IRD002                                            LCA                                          Comp Het                              ar                                *RPGRIP1*                      Frameshift                EXON_15          c.2225_2226delGA

  *RPGRIP1*               Frameshift                EXON_17              c.2795_2796insT                                                                                                                                                           

  IRD012                                            RP                                           Hem                                   xl                                *RPGR*                         Missense                  EXON_8           c.785C\>G

  IRD067                                            RP                                           Hem                                   xl                                *RPGR*                         Missense                  EXON_8           c.814G\>T

  IRD075                                            RP                                           Hem                                   xl                                *RPGR*                         Missense, Splice_region   EXON_2           c.154G\>A

  IRD017                                            RP                                           Hem                                   De novo                           *RPGR*                         Frameshift                EXON_2           c.89delT

  IRD059                  Familiar case             RP                                           Comp Het                              ar                                *TULP1*                        Missense                  EXON_15          c.1590C\>G

  *TULP1*                 Missense                  EXON_13              c.1255C\>T                                                                                                                                                                

  IRD060                  RP                                             Comp Het                ar                                    *TULP1*                           Missense                       EXON_15                   c.1590C\>G       

  *TULP1*                 Missense                  EXON_13              c.1255C\>T                                                                                                                                                                

  IRD041                                            RP                                           Comp Het                              ar                                *TULP1*                        Splice_region             INTRON_14        c.1496-6C\>A

  *TULP1*                 Missense                  EXON_14              c.1445G\>A                                                                                                                                                                

  IRD007                                            USH                                          Comp Het                              ar                                *USH2A*                        Missense                  EXON_63          c.12420T\>G

  *USH2A*                 splice_region, syn        EXON_28              c.5775A\>T                                                                                                                                                                

  IRD009                                            USH                                          Comp Het                              ar                                *USH2A*                        Missense                  EXON_63          c.13546G\>T

  *USH2A*                 splice_region, Missense   EXON_10              c.1645T\>C                                                                                                                                                                

  IRD021                                            RP                                           Comp Het                              ar                                *USH2A*                        Missense                  EXON_69          c.14995A\>G

  *USH2A*                 Missense                  EXON_8               c.1481A\>G                                                                                                                                                                

  IRD023                  Familiar case             RP                   USH                     Comp Het                              ar                                *USH2A*                        Missense                  EXON_13          c.2296T\>C

  *USH2A*                 Frameshift                EXON_3               c.545_548delAAGA                                                                                                                                                          

  IRD024                  RP                        USH                  Comp Het                ar                                    *USH2A*                           Missense                       EXON_13                   c.2296T\>C       

  *USH2A*                 Frameshift                EXON_3               c.545_548delAAGA                                                                                                                                                          

  IRD038                                            RP                                           Comp Het                              ar                                *USH2A*                        Missense                  EXON_13          c.2296T\>C

  *USH2A*                 Missense                  EXON_13              c.2276G\>T                                                                                                                                                                

  IRD084                                            USH                                          Hom                                   ar                                *USH2A*                        Frameshift                EXON_69          c.14977_14978delTT

  IRD034                                            RP                                           Hom                                   ar                                *USH2A*                        Missense                  EXON_63          c.12574C\>T

                                                                                                                                                                                                                                                   

  Patient ID              Protein change            Frequency (%)        Coverage\               Segregation and unaffected siblings   Functional predictions (dbNSFP)   Splicing predictions           Reference                                  
                                                                         (\# reads)                                                                                                                                                                

  Human Splicing Finder   dbscSNV                   SPIDEX                                                                                                                                                                                         

                                                                                                                                                                                                                                                   

  IRD027                                            44.9                 514                                                                                             Broken WT Donor Site           0.999\|0.988              −3.21            PMID: 15494742

  p.Thr459GlnfsX2         47.7                      1179                                                                                                                                                                          PMID: 21911583   

  IRD036                  p.Trp700X                 48.2                 303                                                           .\|..\|N\|A\|.\|.\|.\|.\|.\|D                                                                               PMID: 11702214

  p.Val256Val             47.2                      53                                                                                 Broken WT Donor Site              1.000\|0.952                   −2.43                     PMID: 12037008   

  IRD037                  p.Trp700X                 44.5                 110                                                           .\|..\|N\|A\|.\|.\|.\|.\|.\|D     New Acceptor Site                                        −5.41            PMID: 11702214

  p.Val256Val             48.3                      29                                                                                 Broken WT Donor Site              1.000\|0.952                   −2.43                     PMID: 12037008   

  IRD042                  p.Gly1961Glu              47.1                 1325                                                          D\|DD\|D\|D\|N\|D\|D\|D\|D\|D                                                                               PMID: 9295268

  p.Arg212Cys             49.1                      432                                          D\|DD\|D\|A\|M\|D\|D\|D\|D\|D                                                                                                    PMID: 11726554   

  IRD043                  p.Gly1961Glu              46.9                 796                                                           D\|DD\|D\|D\|N\|D\|D\|D\|D\|D                                                                               PMID: 9295268

  p.Leu541Pro             51.9                      727                                          D\|DD\|D\|A\|M\|D\|D\|D\|D\|D                                                                                                    PMID: 11527935   

  IRD050                  p.Trp821Arg               43.8                 309                                                           D\|DD\|D\|D\|H\|T\|D\|D\|D\|D                                                                               PMID: 11527935

  p.Val767Asp             46.3                      452                                          D\|BB\|D\|D\|M\|D\|T\|D\|D\|D                                                                                                    PMID: 15494742   

  IRD054                  p.Arg2149X                49.1                 422                                                           .\|..\|D\|A\|.\|.\|.\|.\|.\|D     New ESS site                                             −58.3            PMID: 12202497

  p.Gly1961Glu            49.4                      1448                                         D\|DD\|D\|D\|N\|D\|D\|D\|D\|D                                                                                                    PMID: 9295268    

  IRD055                  p.Arg948Cys               52.0                 175                                                           T\|BB\|N\|D\|L\|D\|T\|T\|N\|N                                                                               This study

  p.Val767Asp             51.5                      437                                          D\|BB\|D\|D\|M\|D\|T\|D\|D\|D                                                                                                    PMID: 15494742   

  IRD061                  p.Gly1961Glu              50.0                 729                                                           D\|DD\|D\|D\|N\|D\|D\|D\|D\|D                                                                               PMID: 9295268

  p.Pro1380Leu            55.8                      437                                          D\|DP\|N\|A\|M\|D\|D\|D\|D\|D         New ESS site                                                     −5.44                     PMID: 11726554   

  IRD062                  p.Gly1961Glu              100                  787                                                           D\|DD\|D\|D\|N\|D\|D\|D\|D\|D                                                                               PMID: 9295268

  p.Tyr850Cys             49.4                      176                                          D\|DD\|D\|D\|M\|T\|D\|D\|D\|D                                                                                                    PMID: 23096905   

  IRD073                  p.Asn965Ser               100                  225                                                           D\|DD\|D\|D\|L\|D\|D\|D\|D\|D                                                                               PMID: 9054934

  IRD077                  p.Ala1762Asp              50.8                 259                                                           D\|DD\|D\|A\|M\|D\|D\|D\|D\|D                                                                               PMID: 15192030

  p.Val767Asp             51.4                      752                                          D\|BB\|D\|D\|M\|D\|T\|D\|D\|D                                                                                                    PMID: 15494742   

  IRD047                  p.Arg25Trp                56.0                 348                                                           D\|DD\|U\|D\|M\|D\|D\|D\|D\|D     New Donor Site, New ESS site                                              PMID: 10798642

  IRD057                  p.Ser27Thr                46.8                 344                                                           D\|DD\|U\|D\|H\|D\|D\|D\|D\|D                                                                               This study

  IRD058                  p.Ser27Thr                45.5                 317                                                           D\|DD\|U\|D\|H\|D\|D\|D\|D\|D                                                                               This study

  IRD064                  p.Ser27Thr                47.1                 453                                                           D\|DD\|U\|D\|H\|D\|D\|D\|D\|D                                                                               This study

  IRD010                  p.Asp1413His              49.2                 413                                                           D\|BB\|D\|D\|N\|T\|T\|T\|N\|D                                                                               ClinVar: RCV000082249.5

  p.Lys797SerfsX2         30.1                      163                                                                                                                                                                           This study       

  IRD066                  p.Lys2214X                47.5                 705                                                           .\|..\|D\|A\|.\|.\|.\|.\|.\|D     ESE Site Broken                                          −86.6            This study

  p.Met407GlufsX14        51.1                      225                                                                                                                                                                           PMID: 17724218   

  IRD072                  p.Asp433Gly               53.4                 116                                                           T\|DP\|D\|D\|L\|T\|T\|T\|D\|D     New ESS site, New donor site                                              This study

  p.Thr55SerfsX3          43.2                      243                                                                                                                                                                           PMID: 20690115   

  IRD039                  p.Gly298CysfsX13          100^ \ *∗*^                                                                                                                                                                                    This study

  IRD052                  p.Asn986Ile               51.7                 471                                                           D\|DD\|D\|D\|M\|D\|D\|D\|D\|D                                                                               PMID: 21147909

  p.Gly298CysfsX13        26,7^*∗* ^                258                                                                                                                                                                           This study       

  IRD068                  Thr842Thr                 52.1                 431                                                                                             ESE Site Broken                                                           This study

  p.Gly718Ala             47.1                      153                                          D\|PP\|D\|D\|M\|T\|T\|T\|D\|D                                                                                                    This study       

  IRD085                  p.Arg762Cys               100                  57                                                            D\|DD\|D\|D\|H\|D\|D\|D\|D\|D                                                                               This study

  IRD032                                            47.8                 907                                                                                             Broken WT Donor Site                                     −8.56            PMID: 15657609

  p.Thr383IlefsX13        46.5                      588                                                                                                                                                                           PMID: 15657609   

  IRD029                  p.Gly734Arg               100                  397                                                           D\|DD\|.\|D\|M\|T\|D\|D\|D\|D                                                                               This study

  IRD030                  p.Gly734Arg               100                  397                                                           D\|DD\|.\|D\|M\|T\|D\|D\|D\|D                                                                               This study

  IRD031                  p.Gly734Arg               100                  397                                                           D\|DD\|.\|D\|M\|T\|D\|D\|D\|D                                                                               This study

  IRD035                  p.Pro172LeufsX15          50.5                 521                                                                                                                                                                       This study

  IRD008                                            100                  395                     Brother: Het                                                            Broken WT Donor Site                                                      This study

  IRD013                  p.Arg265Gln               51.7                 319                     n.a.                                  T\|DD\|D\|D\|L\|T\|T\|T\|N\|D                                                                               ClinVar: RCV000178068.1

                          54.7                      75                   Mother: Het                                                                                     0.001\|0.096                                             PMID: 8698075    

  IRD026                  p.Asp190Tyr               44.6                 168                                                           D\|DD\|D\|D\|M\|T\|T\|T\|D\|D                                                                               PMID: 8401533

  IRD016                  p.Pro60Thr                56.1                 278                                                           T\|BB\|N\|N\|L\|T\|T\|T\|N\|N                                                                               PMID: 8595413

  p.Thr108Met             52.8                      108                                          T\|PB\|N\|D\|L\|T\|T\|T\|N\|D                                                                                                    PMID: 8595413    

  IRD033                  p.Leu129ValfsX9           100                  392                                                                                                                                                                       This study

  IRD076                  p.Leu22Pro                100                  495                                                           T\|BB\|D\|D\|M\|D\|D\|D\|N\|D                                                                               PMID: 9801879

  IRD001                  p.Leu22Pro                46.3                 257                     Brother: wt                           T\|BB\|D\|D\|M\|D\|D\|D\|N\|D                                                                               PMID: 9801879

  p.Lys298SerfsX27        98                        150                  Brother: wt                                                                                                                                              PMID: 11462243   

  IRD074                  p.Tyr144Asp               100                  430                     Father: Het                           D\|DD\|D\|D\|M\|D\|D\|D\|D\|D                                                                               PMID: 11462243

  IRD002                  p.Glu743ArgfsX24          48.8                 570                     Father: Het                                                                                                                                       This study

  p.Glu933X               48.8                      400                  Mother: Het                                                                                                                                              This study       

  IRD012                  p.Ala262Gly               100                  280                                                           T\|BB\|N\|N\|L\|D\|T\|T\|N\|N                                                                               This study

  IRD067                  p.Gly272Cys               100                  155                                                           D\|DD\|D\|D\|H\|D\|D\|D\|D\|D                                                                               This study

  IRD075                  p.Gly52Arg                100                  348                                                           D\|DP\|U\|D\|M\|T\|T\|T\|D\|D     Broken WT Donor Site                                                      PMID: 15364249

  IRD017                  p.Phe30SerfsX38           100                  113                     Brother: wt\                                                                                                                                      This study
                                                                                                 Female twin: wt                                                                                                                                   

  IRD059                  p.Ile530Met               50.6                 682                                                           D\|DD\|D\|D\|H\|D\|D\|D\|D\|N                                                                               This study

  p.Arg419Trp             49.5                      645                                          D\|DD\|D\|D\|H\|D\|D\|D\|D\|D                                                                                                    PMID: 25342620   

  IRD060                  p.Ile530Met               51.0                 655                                                           D\|DD\|D\|D\|H\|D\|D\|D\|D\|N                                                                               This study

  p.Arg419Trp             45.3                      575                                          D\|DD\|D\|D\|H\|D\|D\|D\|D\|D                                                                                                    PMID: 25342620   

  IRD041                                            54.1                 727                     Father: Het                                                                                            0.005\|0.419                               PMID: 9660588

  p.Arg482Gln             48.5                      485                  Mother: Het             D\|DD\|D\|D\|H\|D\|D\|D\|D\|D         New Acceptor Site                                                −1.28                     PMID: 22665969   

  IRD007                  p.Cys4140Trp              50.5                 214                                                           D\|DD\|D\|D\|M\|T\|T\|T\|D\|D                                                                               This study

                          49.5                      398                                                                                Broken WT Donor Site              0.998\|0.986                   −4.24                     This study       

  IRD009                  p.Gly4516Trp              53.8                 239                                                           D\|DD\|U\|D\|H\|T\|D\|D\|D\|D                                                                               This study

  p.Cys549Arg             49.2                      566                                          D\|DD\|U\|D\|H\|D\|D\|D\|D\|D                                           0.417\|0.520                                             This study       

  IRD021                  p.Thr4999Ala              51.0                 400                                                           D\|DD\|U\|D\|M\|T\|T\|T\|D\|D                                                                               This study

  p.Tyr494Cys             49.0                      400                                          D\|DD\|N\|D\|L\|T\|T\|T\|D\|D                                                                                                    This study       

  IRD023                  p.Cys766Arg               39.0                 82                                                            D\|DD\|D\|D\|H\|D\|D\|D\|D\|D                                                                               PMID: 23591405

  p.Lys182ArgfsX9         61.4                      202                                                                                                                                                                           This study       

  IRD024                  p.Cys766Arg               43.5                 124                                                           D\|DD\|D\|D\|H\|D\|D\|D\|D\|D                                                                               PMID: 23591405

  p.Lys182ArgfsX9         48.0                      225                                                                                                                                                                           This study       

  IRD038                  p.Cys766Arg               47.2                 89                                                            D\|DD\|D\|D\|H\|D\|D\|D\|D\|D                                                                               PMID: 23591405

  p.Cys759Phe             51.1                      90                                           D\|DD\|D\|A\|H\|D\|D\|D\|D\|D                                                                                                    PMID: 10775529   

  IRD084                  p.Phe4993ProfsX7          100                  483                                                                                                                                                                       PMID: 24944099

  IRD034                  p.Arg4192Cys              100                  515                                                           D\|DP\|N\|D\|M\|D\|D\|D\|D\|D                                                                               PMID: 24498627
  ----------------------- ------------------------- -------------------- ----------------------- ------------------------------------- --------------------------------- ------------------------------ ------------------------- ---------------- -------------------------

ACHM: Achromatopsia; ad: autosomal dominant; ar: autosomal recessive; BMD: best macular disease; Comp Het: compound heterozygous; ESE: exonic splicing enhancer; ESS: exonic splicing silencer; Hem: Hemizygous; Het: heterozygous; Hom: homozygous; LCA: Leber Congenital Amaurosis; nd IRD: inherited retinal degeneration not otherwise specified without precisely defined diagnosis; RP: Retinitis Pigmentosa; STGD: Stargardt Disease; USH: Usher Syndrome; wt: wild-type; xl: X-linked. For nonsynonymous variants, predictions from dbNSFP are reported, comprising scores from the following alghoritms: SIFT \| Polyphen2HDIV Polypehn2HVAR \| LRT \| MutationTaster \| MutationAssessor \| FATHMM \| MetaSVM \| MetaLR \| PROVEAN \| fathmm-MKL. For splicing variants, predictions from Human Splicing Finder, dbscSNV (ada_score\|rf_score) and SPIDEX are reported. For SPIDEX, max dPSI is shown if lower than −1 (maximum mutation − induced change in the percentage of transcripts with the exon spliced in). Familiar case: the patients were from the same family. ^\*^Sanger sequencing was performed to confirm mutation frequency.
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